CSPC Showcases 2025 ESG Progress: RMB 5.81 Billion R&D Spend, 200+ Innovative Drugs in Development

Bulletin Express04-28 19:48

CSPC Pharmaceutical Group Limited (CSPC) released its 2025 Environmental, Social and Governance Report, detailing expanded R&D investment, strengthened quality controls and accelerated decarbonisation initiatives.

• R&D investment reached RMB 5.81 billion, equivalent to 28.2 % of finished-drug revenue, supporting more than 200 innovative and novel-formulation projects—over 90 biologics, 60+ small molecules and 50+ new delivery systems. Four new products and nine generics obtained marketing approval during the year.

• Quality management remained a focal point. All production lines maintained Good Manufacturing Practice certification and the group passed 62 on-site inspections by domestic and international regulators. Internal oversight included 37 system and surprise audits, while 708 quality-system training sessions covered the entire 19,693-strong workforce.

• A three-tier ESG governance framework is in place, with the board assuming ultimate oversight. Double-materiality assessment identified climate change, product quality, innovation and access to healthcare as top priorities.

• Climate and resource initiatives progressed: green electricity consumption totalled 177,823.51 MWh; seven subsidiaries achieved ISO 50001 certification; five factories gained national-level “green factory” status. Comprehensive energy consumption intensity fell to 0.11 tons of standard coal per RMB 10,000 of revenue, and the compliant treatment rate for waste gas, wastewater and solid waste remained at 100 %.

• Workforce metrics highlight diversity and safety. Women represent 48 % of employees and 59 % of middle- and senior-management roles. Nine subsidiaries obtained ISO 45001 certification, with zero work-related fatalities and no confirmed occupational-disease cases reported for 2025.

• Social contributions included RMB 61.55 million in charitable donations, 95,469 volunteer hours and patient-assistance programmes that served more than 100,000 beneficiaries across China.

The report was approved by the board on 25 March 2026 and is available on the Hong Kong Stock Exchange website and the company’s homepage.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment